Industry Partners
AIM thanks the following corporate partners for their continued support in providing resources and education on immunotherapy to the healthcare professional community, helping advance care for patients with cancer.
- About Us
- Resources by Drug Therapy
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources
- About Us
- Resources by Drug Therapy
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources
MENU
- About Us
- Resources by Drug Therapy
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources